indoramin

DRUG INTERACTION

Contraindicated  

Serious Use Alternative  

Monitor Closely  

Minor  

Frequency defined:   

>10% 

Retrograde ejaculated  

1% to 10% 

Orthostatic hypotension 

Dizziness 

Headache 

Insomnia  

Weakness 

Prostate-specific antigen increased  

Diarrhea  

Abdominal pain 

Nasal congestion 

Rhinorrhea 

Sinusitis   

<1% Postmarketing 

Hepatic insufficiency  

Hypersensitivity reaction  

Jaundice  

Pharyngeal edema 

Pruritis 

Swollen tongue  

Syncope  

Urticaria  

Pregnancy consideration: Not enough studies are available for indoramin, therefore not recommended as initial therapy in pregnant women. Few adverse effects were reported in animal reproductive studies. 

Lactation: excretion of indoramin in breast milk is not known.  

Pregnancy category: 

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester. 
• Category B: There is no evidence of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women. 
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women 
• Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category outweigh risks over benefits. These category drugs should be prohibited for pregnant women. 
• Category N: There is no data available for the drug under this category. 

 

Patient information leaflet 

Generic Name: Indoramin 

Pronounced: indoramin  

Why do we use indoramin? 

Indoramin is used for the treatment of hypertension and benign prostatic hyperplasia.